{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:33:43Z","timestamp":1791516823799,"version":"4.3.4"},"reference-count":26,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have revolutionized the management of type 2 diabetes and obesity. Recent evidence suggests these agents may influence athletic performance through effects on body composition, energy metabolism, and cardiovascular function. This narrative review critically evaluates whether incretin therapies could constitute doping under World Anti-Doping Agency (WADA) criteria. We narratively reviewed the literature on incretin pharmacology, metabolic effects relevant to athletic performance, and anti-doping regulations, searching PubMed, Scopus, and Web of Science using terms including \u201cGLP-1 receptor agonists\u201d, \u201cDPP-4 inhibitors\u201d, \u201cdoping\u201d, \u201cathletic performance\u201d, \u201cWADA\u201d, and \u201csports pharmacology\u201d, without date restrictions. GLP-1 RAs (semaglutide, liraglutide, tirzepatide, exenatide) induce substantial weight loss (predominantly fat mass) but also reduce lean mass by 20\u201330% of total weight loss. Preclinical studies demonstrate enhanced exercise endurance, mitochondrial biogenesis, and glucose uptake via GLP-1R\/AMPK signaling. However, clinical trials show no consistent improvement in physical performance in humans. Currently, incretin therapies are not listed on the WADA Prohibited List. While incretin therapies offer theoretical performance-enhancing potential through weight management and metabolic optimization, current evidence does not support classification as doping agents. Continued surveillance is warranted as misuse patterns emerge.<\/jats:p>","DOI":"10.3390\/ijms27146116","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:27:31Z","timestamp":1783531651000},"page":"6116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications\u2014A Narrative Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-2372","authenticated-orcid":false,"given":"Sandro","family":"La Vignera","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5217-9343","authenticated-orcid":false,"given":"Rosita A.","family":"Condorelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4103\/JPBS.JPBS_229_17","article-title":"Sports pharmacology: A medical pharmacologist\u2019s perspective","volume":"10","author":"Malve","year":"2018","journal-title":"J. Pharm. Bioallied Sci."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chrysavgis, L., Mourelatou, N.G., Koloutsou, M.-E., Rozani, S., and Cholongitas, E. (2025). The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262412130"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.21608\/bfsa.2022.271789","article-title":"AN OVERVIEW OF INCRETIN-BASED THERAPIES: PHARMACOLOGY AND FUTURE PERSPECTIVES","volume":"45","author":"Ismail","year":"2022","journal-title":"Bull. Pharm. Sci. Assiut"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Codella, R., Senesi, P., and Luzi, L. (2025). GLP-1 agonists and exercise: The future of lifestyle prioritization. Front. Clin. Diabetes Healthc., 6.","DOI":"10.3389\/fcdhc.2025.1720794"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.diabet.2018.08.010","article-title":"Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2)","volume":"45","author":"Ahmed","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"119300","DOI":"10.1016\/j.bbamcr.2022.119300","article-title":"GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R\/AMPK pathway","volume":"1869","author":"Wu","year":"2022","journal-title":"Biochim. Biophys. Acta BBA-Mol. Cell Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Holt, R.I.G. (2012). Diabetes and Doping. Type 1 Diabetes, Springer.","DOI":"10.1007\/978-0-85729-754-9_8"},{"key":"ref_8","unstructured":"Heuberger, J. (2019). The Clinical Pharmacology of Performance Enhancement and Doping Detection in Sports. [Doctoral Dissertation, Leiden University]."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chiappini, S., Vickers-Smith, R., Harris, D., Pelletier, G.D.P., Corkery, J.M., Guirguis, A., Martinotti, G., Sensi, S.L., and Schifano, F. (2023). Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration\u2019s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals, 16.","DOI":"10.20944\/preprints202306.0611.v1"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gross, K., and Brinkmann, C. (2024). Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1449653"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., Chen, Y., Dai, A., Liang, A., and Ming, Q. (2021). Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors. bioRxiv.","DOI":"10.1101\/2021.07.29.454286"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4172\/2155-6156.1000414","article-title":"Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors","volume":"5","author":"Cornell","year":"2014","journal-title":"J. Diabetes Metab."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Patti, A.M., A Rizvi, A., Giglio, R.V., Stoian, A.P., Ligi, D., and Mannello, F. (2020). Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. J. Clin. Med., 9.","DOI":"10.3390\/jcm9040912"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Diz-Chaves, Y., Mastoor, Z., Spuch, C., Gonz\u00e1lez-Mat\u00edas, L.C., and Mallo, F. (2022). Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179583"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2337\/db22-0745","article-title":"Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-Induced Obesity","volume":"72","author":"Liu","year":"2023","journal-title":"Diabetes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"107927","DOI":"10.1016\/j.phrs.2025.107927","article-title":"Glucagon-like peptide-1 receptor agonists and muscle mass effects","volume":"220","author":"Ceasovschih","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41366-019-0513-y","article-title":"Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob\/ob mice","volume":"44","author":"Xu","year":"2020","journal-title":"Int. J. Obes."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/DMSO.S425642","article-title":"GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway","volume":"16","author":"Xiang","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.2147\/DDDT.S381546","article-title":"An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism","volume":"16","author":"Ren","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/oby.24274","article-title":"Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle","volume":"33","author":"Choi","year":"2025","journal-title":"Obesity"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e13677","DOI":"10.1002\/jcsm.13677","article-title":"The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review","volume":"16","author":"Old","year":"2025","journal-title":"J. Cachex-Sarcopenia Muscle"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112225","DOI":"10.1016\/j.mce.2024.112225","article-title":"Liraglutide promotes UCP1 expression and lipolysis of adipocytes by promoting the secretion of irisin from skeletal muscle cells","volume":"588","author":"Zhang","year":"2024","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jeromson, S., Baranowski, B., Akcan, M., Waters, B.D., Eisner, K., Bellucci, A., Trang, S., Abolhassani, A., Tello-Palencia, M.A., and Schweitzer, A. (2025). Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet-induced obesity. J. Physiol.","DOI":"10.1113\/JP289449"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Abuetabh, Y., Schmidt, M.A., Naganuma, M., Vaka, R., El-Ghiaty, M.A., Braun, S., Kwan, E.A., Zolondek, M.C., Sahid, D., and Khan, L. (2026). Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters. J. Clin. Investig.","DOI":"10.1172\/jci.insight.201810"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.obpill.2024.100121","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: A narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obes. Pillars"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/dta.3572","article-title":"Insulin-mimetic peptides in sports drug testing","volume":"15","author":"Thomas","year":"2023","journal-title":"Drug Test. Anal."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:45:26Z","timestamp":1783683926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":26,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27146116"],"URL":"https:\/\/doi.org\/10.3390\/ijms27146116","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}